Xcout IntelSign inSubscribe

CollPlant Biotechnologies Ltd. competitors & alternatives

CLGNBiotechnologyRehovot, Israel

The 12 closest competitors and alternatives to CollPlant Biotechnologies Ltd. among biotechnology companies — ranked by similarity to what CollPlant Biotechnologies Ltd. actually does, not by market-cap band.

$4.5MMarket cap
39Employees
12Competitors listed

Subscribe to see CollPlant Biotechnologies Ltd.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

About CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd. is a biotechnology company headquartered in Rehovot, Israel. The company focuses on regenerative medicine and reports its financial results in U.S. dollars.

CollPlant Biotechnologies Ltd. at a glance

CollPlant Biotechnologies Ltd. is a biotechnology company headquartered in Rehovot, Israel, founded in 1981. It is publicly listed (CLGN) with a market capitalisation of $4.5M. Xcout tracks 31 named people at CollPlant Biotechnologies Ltd., including Yehiel Tal (CEO & Chairman).

CollPlant Biotechnologies Ltd. leadership

  • Yehiel TalCEO & Chairman
  • Eran RotemDeputy Chief Executive Officer & Chief Financial Officer
  • Hadas Dreiher HorowitzVice President of Human Resources
  • Oded ShoseyovFounder & Chief Scientist
  • Prof. Oded ShoseyovFounder and Chief Scientist
  • Oren FahimipoorVice President of Operations

25 more named people on record for CollPlant Biotechnologies Ltd., with roles, board committees and tenure — see the full roster →

Top 12 CollPlant Biotechnologies Ltd. competitors

Ranked by semantic similarity — how close each company is to CollPlant Biotechnologies Ltd. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.

Organogenesis Holdings Inc.ORGO · BiotechCanton, United States
69% matchPublic

Biotech

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.

Market cap$162.8M
Employees869
Organogenesis Holdings Inc. competitors & alternatives →
ADRバイオメディカルホールディングス3750 · BiotechnologyTokyo, Japan
65% matchPublic

Similar biotechnology company

Operating from its Tokyo headquarters, Cytori Cell Research Institute, Inc., established in 2004 (originally FRACTALE Corporation), specializes in the comprehensive research, development, production, and distribution of medical devices related to cell therapy throughout Japan. The company offers various cell therapy kits and continuously advances cellular treatment technologies through ongoing research and development. Its active development pipeline includes ECCI-50, designed for the treatment of male stress urinary incontinence and hepatic cirrhosis, and Cyt-006, formulated to prevent postoperative adhesion after primary rectal cancer surgery. Additionally, Cytori conducts extensive clinical trials and investigations into cell-based therapies for a wide array of conditions and applications, such as the repair of anterior cruciate ligaments and bones, burn scar remediation, chronic wound healing, critical limb ischemia, treatment of anal and Crohn's disease fistulas, and erectile dysfunction. Beyond its primary biotechnological focus, the company also participates in the real estate sector, encompassing investment, ownership, development, leasing, and management of properties and hotels, as well as providing real estate brokerage services.

Market cap$44.8M
Employees13
ADRバイオメディカルホールディングス competitors & alternatives →

Analyze another company

Search any company we track to see its competitive set.

Or describe a company

Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.

See the full profile of CollPlant Biotechnologies Ltd. and its market

Funding, investors, tech stack, hiring signals, leadership and corporate events — for CollPlant Biotechnologies Ltd.and every competitor above — in one live dashboard.

Subscribe to Xcout Intel →